Let's hope so! They are the evt sponsors, of which we have heard nothing. What dose levels have been passed, what data/biomarkers have been acquired? This is all very standard reporting for a company that is informing their shareholders of how trials are progressing. It is very disingenuous, but not surprising, that acceptance of an abstract with no data they think meets one of their self reported milestones of 'interim data'. Get a deal done, get it to a competent team that can move it forward at a rate the patients deserve!
KZA Price at posting:
16.5¢ Sentiment: Hold Disclosure: Held
